Mind Medicine (MindMed) Inc. announced that in collaboration with University Hospital Basel's Liechti Laboratory, it has discovered and filed a patent application in the United States (preserving all worldwide rights) for a neutralizer technology intended to shorten and stop the effects of an LSD trip during a therapy session.
This discovery, when further developed, may act as the 'off-switch' to an LSD trip.
MindMed is the leading psychedelic pharmaceutical company and the Liechti Laboratory is the leading research center focused on the pharmacology of psychedelic substances.
The invention may help reduce the acute effects of a psychedelic drug and help shorten the hallucinogenic effects when required by a patient or medical professional.
Chief Operating Officer
Head of Corporate Development
Chief Financial Officer
Donald Gehlert, PhD
Chief Scientific Officer
Co-Founder, Director & Co-CEO
EVP, Technical Operations
Director of Operations & Administration
Senior Director, Business Operations and Development
Scott Freeman, MD
Co-Founder, Chief Medical Officer
Stephen L. Hurst, JD
Co-Founder, Executive Chair & Co-CEO